Herein, we report the results of a phase 3 trial that compared gefitinib plus pemetrexed with platinum (chemotherapy) with gefitinib alone for the first-line treatment in patients with asymptomatic EGFR-mutant NSCLC brain metastases. Here, EGFR is linked to non-small cell lung carcinoma.